Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11881111 | 1.00 | CYP1A2 (0.45) | CYP1A2SIRT2TP53PPARGKMT2A | |
| Potassium Ion SCHEMBL29744473 | 0.98 | CYP1A2 (0.44) | CYP1A2SIRT2TP53PPARGKMT2A | |
| SCHEMBL891524 | 0.75 | — | — | |
| SCHEMBL17831602 | 0.75 | — | — | |
| SCHEMBL11872992 | 0.72 | CYP1A2 (0.40) | CYP1A2 | |
| SCHEMBL11876042 | 0.72 | CYP1A2 (0.40) | CYP1A2 | |
| SCHEMBL11871993 | 0.69 | CYP1A2 (0.37) | CYP1A2 | |
| SCHEMBL310717 | 0.68 | CYP1A2 (0.58) | CYP1A2SIRT2TP53PPARG | |
| SCHEMBL13477018 | 0.68 | CYP1A2 (0.58) | CYP1A2SIRT2TP53PPARG | |
| SCHEMBL30740436 | 0.68 | TP53 (0.39) | CYP1A2SIRT2TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3618358-B1 | A METHOD FOR DEEP PACKET INSPECTION IN SOFTWARE DEFINED NETWORKS | ORCKIT IP LLC (US) | 2024-05-29 | — | — | EP | claimed |
| US-20240024268-A1 | Methods for Dopamine Modulation in Human Neurologic Diseases | SACKNER BERNSTEIN JONATHAN (US) | 2024-01-25 | — | — | US | claimed |
| US-11806326-B2 | Methods for dopamine modulation in human neurologic diseases | SACKNER BERNSTEIN JONATHAN (US) | 2023-11-07 | — | — | US | claimed |
| US-20210052531-A1 | Methods for Dopamine Modulation in Human Neurologic Diseases | SACKNER BERNSTEIN JONATHAN (US) | 2021-02-25 | — | — | US | claimed |
| EP-3749290-A1 | METHODS FOR DOPAMINE MODULATION IN HUMAN NEUROLOGIC DISEASES | Sackner-Bernstein, Jonathan (US) | 2020-12-16 | — | — | EP | claimed |
| EP-3655036-A1 | COMPOSITIONS FOR TREATING STRESS-RELATED DISORDERS | Hoffman Technologies, Inc. (US) | 2020-05-27 | — | — | EP | claimed |
| WO-2019147934-A1 | METHODS FOR DOPAMINE MODULATION IN HUMAN NEUROLOGIC DISEASES | SACKNER BERNSTEIN JONATHAN (US) | 2019-08-01 | — | — | WO | claimed |
| WO-2019018633-A1 | COMPOSITIONS FOR TREATING STRESS-RELATED DISORDERS | HOFFMAN TECHNOLOGIES, INC. (US) | 2019-01-24 | — | — | WO | claimed |
| US-20180243210-A1 | METHOD FOR TREATING INTESTINAL FIBROSIS | SIGMOID PHARMA LIMITED (IE) | 2018-08-30 | — | — | US | claimed |
| EP-2642978-A2 | IMMUNOMODULATORY COMPOSITIONS COMPRISING HYDRALAZINE FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Sigmoid Pharma Limited (IE) | 2013-10-02 | — | — | EP | claimed |
| WO-2012069658-A2 | IMMUNOMODULATORY COMPOSITIONS | SIGMOID PHARMA LIMITED (IE) | 2012-05-31 | — | — | WO | claimed |
| US-12564622-B2 | Preventing cytokine release syndrome | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | disclosed |
| EP-4495238-A2 | TARGETING EGLN1 IN CANCER | The Broad Institute, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | NUVAMID SA (CH) | 2024-12-19 | — | — | US | disclosed |
| US-5654152-A | Method of measuring enzyme activity by using a column having an immobilized substrate | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1997-08-05 | — | — | US | disclosed |
| EP-0329190-B1 | Filler for measuring enzyme activity, column packed with the filler, and method of measuring enzyme activity using the column | SHOWA DENKO KK (JP) | 1995-09-13 | — | — | EP | disclosed |
| EP-0329190-A2 | Filler for measuring enzyme activity, column packed with the filler, and method of measuring enzyme activity using the column | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1989-08-23 | — | — | EP | disclosed |
| US-3835170-A | HYPOTENSIVE AGENT, OUDENONE, ITS SALTS AND PROCESSES FOR PRODUCTION AND PREPARATION THEREOF | MICROBIAL CHEM RES FOUND | 1974-09-10 | — | — | US | disclosed |
| US-3835170-A | HYPOTENSIVE AGENT, OUDENONE, ITS SALTS AND PROCESSES FOR PRODUCTION AND PREPARATION THEREOF | MICROBIAL CHEM RES FOUND | 1974-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564622-B2 | Preventing cytokine release syndrome | CRH, IL1B, IL1A | CYP1A2 1254/4885SIRT2 3929/4885TP53 4235/4885 |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | SNCA, NLN, PARK7 | CYP1A2 3123/4885SIRT2 1574/4885TP53 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.